APM
INZY

Avidity Partners Management’s Inozyme Pharma INZY Stock Holding History

Avidity Partners Management’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-9,683
Closed -$200K – 107
2020
Q4 		$200K Sell
9,683
-52,172
-84% -$1.24M 0.01% 96
2020
Q3 		$1.63M Buy
+61,855
New +$1.54M 0.08% 64

Other funds holding INZY

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Avidity Partners Management's INZY Position: Q1 2021 in Review

Avidity Partners Management sold out of Inozyme Pharma (INZY) in Q1 2021, closing a stake of 9,683 shares — an estimated $200K sold.

Avidity Partners Management first reported a position in INZY in Q3 2020 and held it in 2 quarters. The position peaked at $1.63M in Q3 2020. 55 funds tracked by Wall St. Rank hold INZY as of Q1 2021.

  • Avidity Partners Management reported no remaining Inozyme Pharma position as of Q1 2021 after selling out during the quarter.
  • Avidity Partners Management sold 9,683 Inozyme Pharma shares in Q1 2021, an estimated $200K.
  • Avidity Partners Management first reported a position in Inozyme Pharma in Q3 2020 and held it in 2 quarters.
  • Avidity Partners Management's Inozyme Pharma position peaked at $1.63M in Q3 2020.
  • 55 funds tracked by Wall St. Rank held Inozyme Pharma as of Q1 2021.

Based on Avidity Partners Management's 13F filing for Q1 2021, filed 17 May 2021.